Investor presentation
Logotype for Heartbeam Inc

Heartbeam (BEAT) Investor presentation summary

Event summary combining transcript, slides, and related documents.

Logotype for Heartbeam Inc

Investor presentation summary

12 Nov, 2026

Platform and cleared use

  • Cable-free, card-sized system uses patented TriCor 3D signal collection to synthesize a 12-lead ECG; 26 issued patents worldwide.

  • The HeartBeam System received FDA clearance for arrhythmia assessment in Dec 2024; 12-lead ECG synthesis software received clearance in Dec 2025.

  • FDA-cleared use is limited to arrhythmia assessment; heart attack detection, AI algorithms, patch and remote products are not cleared for sale.

  • Clinical evidence includes 1,000+ patients, 17 papers and presentations, 300+ users and 22,000+ recordings.

Commercial launch and offering

  • Multiple commercial agreements cover NY metro, Dallas, South Florida and Southern California; first orders shipped and initial patients onboarded in Q2 2026, with increasing order magnitude in Q3.

  • 24/7 reader service, onboarding and customer success are live; the system is being integrated into new-patient intake at concierge practices.

  • Annual patient subscription includes equipment, routine recordings, unlimited automated arrhythmia reads estimated from end-2026, and credits for cardiologist interpretation in under 30 minutes.

  • Planned first-year post-launch features include telehealth, wearable integration, community features, AI wellness algorithms and physician assessments of interval trends.

Market and growth strategy

  • Addressable opportunity is presented as 50M+ at-risk patients and a $40B cardiac platform market, using a $750 annual patient spend assumption pending further validation.

  • Initial direct-pay entry targets 1.5M concierge and preventive cardiology patients, with a 3.5M broader patient-pay expansion opportunity.

  • June 2026 strategy shift prioritizes licensing the 3D ECG signal platform through established distribution channels, including health systems, ECG OEMs, monitor manufacturers and wearable companies.

  • Longer-term opportunity includes serving 50M+ patients across multiple applications and form factors, with partner and distribution discussions underway.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Heartbeam